Work

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8011

Authors: Amita Patnaik, Mark A. Socinski, Matthew A. Gubens, Leena Gandhi, James Stevenson, Robert D. Bachman, Jennifer Bourque, Joy Yang Ge, Ellie Im, Shirish M. Gadgeel

Institutions: South Texas Accelerated Research Therapeutics, University of Pittsburgh, University of California, San Francisco, Dana-Farber Cancer Institute, Cleveland Clinic, Merck & Co., Inc., Rahway, NJ, USA (United States), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2472661106

Cites:

Cited by: 69

Related to: 10